Phillip Md Et Al Frost Acquires 3,600 Shares of Opko Health, Inc. (OPK) Stock

Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 3,600 shares of the company’s stock in a transaction on Wednesday, July 12th. The stock was acquired at an average price of $6.12 per share, with a total value of $22,032.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $18,781,980.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, July 14th, Phillip Md Et Al Frost acquired 12,600 shares of Opko Health stock. The stock was acquired at an average price of $6.16 per share, with a total value of $77,616.00.
  • On Monday, July 10th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was purchased at an average cost of $6.19 per share, for a total transaction of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The stock was purchased at an average cost of $6.29 per share, for a total transaction of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost bought 60,800 shares of Opko Health stock. The stock was purchased at an average cost of $6.44 per share, for a total transaction of $391,552.00.
  • On Friday, June 30th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was purchased at an average cost of $6.58 per share, for a total transaction of $23,688.00.
  • On Wednesday, June 28th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $6.87 per share, for a total transaction of $12,366.00.
  • On Tuesday, June 27th, Phillip Md Et Al Frost bought 21,800 shares of Opko Health stock. The stock was purchased at an average cost of $6.77 per share, for a total transaction of $147,586.00.
  • On Monday, June 26th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $6.97 per share, for a total transaction of $12,546.00.
  • On Thursday, June 22nd, Phillip Md Et Al Frost bought 131,000 shares of Opko Health stock. The stock was purchased at an average cost of $6.72 per share, for a total transaction of $880,320.00.
  • On Thursday, June 15th, Phillip Md Et Al Frost bought 200,000 shares of Opko Health stock. The stock was purchased at an average cost of $6.43 per share, for a total transaction of $1,286,000.00.

Shares of Opko Health, Inc. (NASDAQ:OPK) traded down 0.9087% on Monday, hitting $6.0743. 1,074,759 shares of the stock were exchanged. The company has a 50 day moving average of $6.59 and a 200 day moving average of $8.10. Opko Health, Inc. has a 52-week low of $5.99 and a 52-week high of $12.15. The company’s market cap is $3.40 billion.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The business’s revenue was up 1.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.02) EPS. Equities research analysts forecast that Opko Health, Inc. will post ($0.20) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/07/17/phillip-md-et-al-frost-acquires-3600-shares-of-opko-health-inc-opk-stock.html.

Several equities research analysts recently issued reports on OPK shares. Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 price target on shares of Opko Health in a report on Monday, June 12th. BidaskClub raised shares of Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $19.50 price target on shares of Opko Health in a report on Tuesday, June 6th. Finally, Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $16.58.

A number of institutional investors have recently made changes to their positions in OPK. BlackRock Inc. raised its position in shares of Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock valued at $181,163,000 after buying an additional 22,449,752 shares in the last quarter. Norges Bank purchased a new position in shares of Opko Health during the fourth quarter valued at approximately $30,421,000. State Street Corp raised its position in shares of Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after buying an additional 3,138,685 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in shares of Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock valued at $40,489,000 after buying an additional 1,944,549 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock valued at $210,576,000 after buying an additional 1,112,843 shares in the last quarter. 23.65% of the stock is owned by institutional investors and hedge funds.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply